Clinical Trials Logo

B-cell Non-Hodgkin's Lymphoma clinical trials

View clinical trials related to B-cell Non-Hodgkin's Lymphoma.

Filter by:

NCT ID: NCT04697290 Suspended - Clinical trials for B-cell Non-Hodgkin's Lymphoma

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

Start date: March 10, 2022
Phase: Early Phase 1
Study type: Interventional

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory or relapsed B-NHL.

NCT ID: NCT04637763 Recruiting - Lymphoma Clinical Trials

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Start date: May 26, 2021
Phase: Phase 1
Study type: Interventional

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

NCT ID: NCT03639181 Recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

Start date: October 15, 2018
Phase: Phase 2
Study type: Interventional

An open-label, single-arm, phase II clinical study of anti-PD-1 antibody GB226 in treatment of recurrent or refractory B-cell non-Hodgkin's lymphoma (B-NHL)

NCT ID: NCT03417414 Not yet recruiting - Clinical trials for B Cell Non-Hodgkin's Lymphoma

Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?

Start date: March 1, 2018
Phase: N/A
Study type: Observational

This is an observational cohort study of patients with a new diagnosis of B cell Chronic Lymphocytic Leukemia or B cell Non-Hodgkin's Lymphoma who will receive an anti-CD20 monoclonal antibody treatment during the induction phase of their treatment. Throughout the study, patients will have four blood draws at specified time points throughout the study. The initial blood draw will be analysed test patients for Cytomegalovirus and conduct a g-NK cell analysis. The final three blood draws will be conducted to analyse the g-NK cells at specified time points. The objectives of this study are to: 1) characterize the frequency of CMV (+) and g-NK (+) individuals in the B-NHL and B-CLL populations, 2) Determine changes in circulating g-NK cells during and after anti-CD20 monoclonal antibody containing remission induction chemotherapy and 3) Evaluate whether the presence of g-NK cells improve the outcome of anti-CD20 monoclonal antibody containing remission induction treatment of patients with B-NHL or B-CLL.

NCT ID: NCT03105596 Not yet recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

Start date: April 11, 2017
Phase: Phase 2
Study type: Interventional

This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).

NCT ID: NCT02787239 Completed - Clinical trials for B-cell Non Hodgkin's Lymphoma

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

Start date: October 2015
Phase: Phase 3
Study type: Interventional

Multicenter, Randomized, Double-blind, Parallel, Phase III Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and MabThera in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

NCT ID: NCT02584920 Completed - Clinical trials for B-cell Non Hodgkin's Lymphoma

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

Start date: October 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Randomised, double-blind, parallel group study to compare PK and PD profiles between HLX01 and rituximab (MabThera®) in patients with CD20+ B-cell Lymphoma.

NCT ID: NCT02564744 Completed - Clinical trials for Diffuse Large B-Cell Lymphoma

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Start date: June 5, 2016
Phase: Phase 2
Study type: Interventional

The primary purpose of the study was to determine the safety and tolerability, anti-tumor activity of the proposed Debio 1562 dose regimens in combination with rituximab.

NCT ID: NCT02456207 Recruiting - Clinical trials for B-cell Non Hodgkin's Lymphoma

A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to assess the pharmacokinetic (PK) similarity of SCT400 versus rituximab (MabThera®) in patients with CD20+ B-cell Non-Hodgkin's Lymphoma. The secondary objective of the study is to evaluate the pharmacodynamics (PD) and safety of SCT400 versus rituximab (MabThera®), as well as the presence of human anti-chimeric antibodies (HACA).

NCT ID: NCT02206308 Completed - Clinical trials for B-cell Non Hodgkin's Lymphoma

Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.

Start date: May 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether SCT400 is safe and effective in the treatment of B-cell Non Hodgkin's lymphoma